MicroRNAs in Colon and Rectal Cancer--Novel Biomarkers from Diagnosis to Therapy.

MicroRNAs in Colon and Rectal Cancer--Novel Biomarkers from Diagnosis to Therapy. Endocr Metab Immune Disord Drug Targets. 2020 May 05;: Authors: Yang Y, Meng WJ, Wang ZQ Abstract Colorectal cancer (CRC) is one of the most common cancers and a significant cause of tumor-related death worldwide. Traditional biomarkers, such as CEA and CA199, are not sensitive enough to provide useful information for early diagnosis and treatment and are rather used to track clinical progression of disease. There is growing evidence that microRNAs (miRNA) are potentially superior to traditional biomarkers as a promising non-invasive biomarker for the timely diagnosis, and prediction of prognosis or treatment response in management of CRC. In this review, we collected the latest studies on the dysregulation of miRNAs expression in CRC and the potential for miRNAs to serve as biomarkers. Given the limitations of miRNA as discussed in this paper, its clinical applications as a diagnostic biomarker should be limited to use in combination with other biomarkers. Further research is necessary to elucidate the clinical applications of miRNA in therapy for CRC. PMID: 32370729 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research